← Back to headlines
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-3 Study of TALZENNA®
Pfizer Inc. has announced positive topline results from its Phase 3 TALAPRO-3 study of TALZENNA®, indicating successful outcomes for the drug.
25 Mar, 18:52 — 25 Mar, 18:52
Sources
Showing 1 of 1 sources
